Navigation Links
Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial
Date:10/21/2013

BLUE BELL, Pa., Oct. 21, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients. Under a 2011 collaborative development agreement, Inovio's affiliate, VGX International Inc. (KSE: 011000), is fully funding and conducting the study at multiple sites in Korea. Inovio is also planning to evaluate this hepatitis C (HCV) vaccine in additional clinical studies in the U.S. beginning in 2014.

Dr. J. Joseph Kim, Inovio's President and CEO, said, "More effective antiviral drugs have changed the prognosis for patients with hepatitis C; however, treatment failures remain and combination with an immunotherapeutic approach could make the difference for many patients. In preclinical studies, Inovio's HCV immunotherapy has shown to generate powerful T cell responses in the liver, which could be important in clearing HCV-infected liver cells.  We have already shown in published clinical studies that our vaccines generate best-in-class T-cell responses. In this study, the effects of Inovio's HCV immunotherapy will be directly tested in patients who have previously failed standard drug therapies. We look forward to entering the hepatitis C treatment arena, which is one of the fastest-developing markets in healthcare, with a projected value of $20 billion by the end of the decade."  

This study is a multi-center, open-label, dose-escalating phase I trial in which 18 subjects will be divided into three groups and given four monthly vaccinations of 1 mg, 3 mg and 6 mg doses of VGX-6150, respectively. Individuals with chronic HCV who failed previous standard of care therapy with pegylated interferon and ribavirin or triple therapy with standard of care and direct-acting antiviral agents
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals to Participate in Immunotherapy Panel and Present at the 12th Annual BIO Investor Forum
2. Inovio Pharmaceuticals Targets Transformation of Monoclonal Antibody Therapies
3. Inovio Pharmaceuticals to Present at Investor Conferences and Town Hall Los Angeles
4. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
5. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
6. Inovio Pharmaceuticals Malaria DNA Vaccine Demonstrates Robust Immune Responses in Animal Models
7. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
8. Inovio Pharmaceuticals Responds to Market Activity
9. Inovio Pharmaceuticals Potent hTERT DNA Cancer Vaccine Shows Potential to Reduce Tumors and Prevent Tumor Recurrence
10. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
11. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... N.J. , July 25, 2014  Acsis ... brand protection and serialization solutions, has recently posted ... that addresses current and future needs for ... for the old supply chain model no longer ... in technology, including the growth of mobile technology, ...
(Date:7/25/2014)...  IDEXX Laboratories, Inc. (NASDAQ: IDXX ) ... 2014 increased 11% versus the prior year period to ... second quarter of 2014 versus the prior year period ... inventory 2 . Earnings per diluted share ("EPS") for ... the prior year period to $1.10."In the second quarter, ...
(Date:7/25/2014)... 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... and report second quarter 2014 financial results before the ... 2014. That same day, Arena will host a conference ... a.m. Pacific Time). The conference call ... and 914.495.8552 for international callers. Please specify to the ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2IDEXX Laboratories Announces Second Quarter Results 2IDEXX Laboratories Announces Second Quarter Results 3IDEXX Laboratories Announces Second Quarter Results 4IDEXX Laboratories Announces Second Quarter Results 5IDEXX Laboratories Announces Second Quarter Results 6IDEXX Laboratories Announces Second Quarter Results 7IDEXX Laboratories Announces Second Quarter Results 8IDEXX Laboratories Announces Second Quarter Results 9IDEXX Laboratories Announces Second Quarter Results 10IDEXX Laboratories Announces Second Quarter Results 11IDEXX Laboratories Announces Second Quarter Results 12IDEXX Laboratories Announces Second Quarter Results 13IDEXX Laboratories Announces Second Quarter Results 14IDEXX Laboratories Announces Second Quarter Results 15IDEXX Laboratories Announces Second Quarter Results 16IDEXX Laboratories Announces Second Quarter Results 17IDEXX Laboratories Announces Second Quarter Results 18IDEXX Laboratories Announces Second Quarter Results 19IDEXX Laboratories Announces Second Quarter Results 20IDEXX Laboratories Announces Second Quarter Results 21IDEXX Laboratories Announces Second Quarter Results 22IDEXX Laboratories Announces Second Quarter Results 23IDEXX Laboratories Announces Second Quarter Results 24IDEXX Laboratories Announces Second Quarter Results 25IDEXX Laboratories Announces Second Quarter Results 26IDEXX Laboratories Announces Second Quarter Results 27IDEXX Laboratories Announces Second Quarter Results 28IDEXX Laboratories Announces Second Quarter Results 29IDEXX Laboratories Announces Second Quarter Results 30IDEXX Laboratories Announces Second Quarter Results 31IDEXX Laboratories Announces Second Quarter Results 32IDEXX Laboratories Announces Second Quarter Results 33IDEXX Laboratories Announces Second Quarter Results 34Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2
(Date:7/28/2014)... Dr. Alan Xenakis, MD announced today the release of ... new book, DOC X MD Funny Feelings translates ... style with humor and medical accuracy. The book is creatively ... answers to those age-old questions that most folks are embarrassed ... do mosquitoes bite some and not others? Why do folks ...
(Date:7/28/2014)... Cuidado Casero , an organization of Medicare ... PHC in Texas, New Mexico, New Jersey, Virginia, and Puerto ... Texas Chapter of PAM’s 2014 Gala. , North Texas ... The North Texas chapter was created by a handful of ... improving medical care for the indigent in Peru. The chapter ...
(Date:7/27/2014)... Hyaluronic Acid can hold 1,000 times ... to the power of Hyaluronic Serums. , "Hyaluronic acid ... of Sublime Beauty®. "But like collagen, it diminishes with ... improves skin moisture-retention and radiance." , Hyaluronic acid ... healthy and beautiful look. Key Ingredients in the serum ...
(Date:7/27/2014)... (PRWEB) July 27, 2014 Manufacturers of ... with organic ways to achieve a younger appearance. The ... buyer's guide to help men and women explore the ... The details that are presented in the posted guide ... price information for consumers. On drawback to some natural ...
(Date:7/27/2014)... Two new pill-only antiviral drug regimens could provide shorter, ... the majority of patients infected with hepatitis C, even ... of two studies published in The Lancet . ... which is the most common genotype in the USA, ... of the most difficult to treat. , Around 150 ...
Breaking Medicine News(10 mins):Health News:New Book by Alan P. Xenakis, MD Reveals Mind and Body Mysteries 2Health News:Cuidado Casero Sponsors Peruvian American Medical Society (PAMS) Gala 2Health News:Aging or Dry Skin Benefits from Hyaluronic Serum; Now 30% Off Sale at Sublime Beauty® 2Health News:Natural Eye Cream Buyer's Guide Published Online at Consumer News Website 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3
... recent issue of the journal Thorax, researchers have emphasized// ... looked into the data provided by 2401 subjects who ... and incidence of tuberculosis disease. Of the total ... skin test. The research results have showed that the ...
... is an important component of mammal’s daily life and more so ... are known to sleep for over 18 hours. However, it is ... has been reported in Nature that newborn bottlenose dolphins and killer ... Their moms manage with only a wink or two than the ...
... has published a major retrospective study that indicates // that ... infertility. ,Dr. Louise A. Brinton, of the National ... U.S. women treated for infertility between 1965 and 1988. She ... general population. The women were followed for a median of ...
... when in the womb of the mother, may have asthma ... had conducted an 11-year observation of incidence of asthma and ... significantly related to incidence of asthma in childhood. Passive smoking ... the incidence of asthma in children. ,Researchers are of ...
... (RPI), they have stated that have received the ... store in the US, for outstanding performance in the ... company with more than 1.3 million associates worldwide and ... , ,RPI is based in Jacksonville, Florida, USA ...
... who had long earlier published their findings on strong links ... up with the results from the next part of the ... ,The follow up data of the research point out ... regularly through their childhood are four times as likely to ...
Cached Medicine News:
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: